Open Label Study to Evaluate Long Term Efficacy, Safety and Tolerability of Repeated Dosing in Subjects with Crohn's Disease and Who Participated and Successfully Completed M14-115

Overview

About this study

This study will evaluate the long term efficacy, safety, and tolerability of repeated administration of adalimumab in subjects with Crohn's disease.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Subject successfully enrolled in and completed Study M14-115, including the Week 12 ileocolonoscopy.

Exclusion Criteria:

  • If the Week 12 (Study M14-115) colonoscopy shows evidence of dysplasia or malignancy.
  • Subject is not in compliance with prior and concomitant medication requirements throughout M14-115.
  • Subject who developed active Tuberculosis (TB) during M14-115, or subject who is non compliant with prophylaxis for latent TB initiated per M14-115 procedures

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status

Rochester, Minn.

Mayo Clinic principal investigator

Edward Loftus, M.D.

Closed for enrollment

More information

Publications

Publications are currently not available

Additional contact information

Non-cancer trials contact form

Phone: 800-664-4542 (toll-free)

International patient clinical studies questions